Literature DB >> 1309424

IgM antibody response in acute hepatitis C viral infection.

J M Clemens1, S Taskar, K Chau, D Vallari, J W Shih, H J Alter, J B Schleicher, L T Mimms.   

Abstract

IgM antibody against hepatitis C virus (IgM anti-HCV) was measured in serial samples from 15 transfusion recipients in whom posttransfusion chronic non-A, non-B hepatitis (NANBH) developed and three plasmapheresis donors during acute HCV infection using recombinant proteins derived from three immunodominant regions: core, NS-3, and NS-4 (c100). IgM anti-HCV core was detected in 13 of 15 posttransfusion patients. Nine of these patients had transient, acute-phase IgM anti-HCV core detected coincidentally or earlier than active IgG anti-HCV core response. The average duration of IgM anti-HCV core reactivity was 8.1 +/- 3.7 weeks. One patient lacking an IgM anti-HCV core response had detectable IgM anti-HCV NS-3 during the acute phase. Passive transfer of IgM anti-HCV was not observed in these posttransfusion cases, in contrast to the high frequency observed for IgG anti-HCV. Late IgM anti-HCV was detectable against core, c100, and NS-3 in three, two, and one posttransfusion patients, respectively. These data indicate that IgM anti-HCV core is a useful acute-phase marker in HCV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309424

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.

Authors:  L M Lagging; K Meyer; R J Owens; R Ray
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 2.  Current molecular methods for the detection of hepatitis C virus in high risk group population: A systematic review.

Authors:  Rushna Firdaus; Kallol Saha; Aritra Biswas; Provash Chandra Sadhukhan
Journal:  World J Virol       Date:  2015-02-12

Review 3.  Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

Authors:  Lynn B Dustin; Edgar D Charles
Journal:  Antivir Ther       Date:  2012-12-07

4.  Long-term serologic follow-up of hepatitis C virus-seropositive homosexual men.

Authors:  O K Ndimbie; S Nedjar; L Kingsley; P Riddle; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

5.  Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection.

Authors:  P J Chen; J T Wang; L H Hwang; Y H Yang; C L Hsieh; J H Kao; J C Sheu; M Y Lai; T H Wang; D S Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

6.  Risk of hepatitis C virus (HCV) transmission by anti-HCV-negative blood components in Austria and Germany.

Authors:  J Riggert; D W Schwartz; A Uy; G Simson; F Jelinek; H Fabritz; W R Mayr; M Köhler
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

7.  Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein.

Authors:  M Chen; A Sönnerborg; M Sällberg
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

8.  IgM and IgA antibodies generated against hepatitis C virus core antigen in patients with acute and chronic HCV infection.

Authors:  S Sato; S Fujiyama; M Tanaka; M Goto; Y Taura; S Kawano; T Sato; H Yasuo
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

9.  Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.

Authors:  R E Swann; P Mandalou; M W Robinson; M M Ow; S K H Foung; J McLauchlan; A H Patel; M E Cramp
Journal:  J Viral Hepat       Date:  2016-07-13       Impact factor: 3.728

Review 10.  Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries.

Authors:  Anoop Kumar; Manoj Kumar Rajput; Deepika Paliwal; Aakanksha Yadav; Reba Chhabra; Surinder Singh
Journal:  Indian J Med Res       Date:  2018-05       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.